tetano
Editor, Senior Moderator
J Med Virol
. 2025 Feb;97(2):e70235.
doi: 10.1002/jmv.70235. Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia
Eric Kalo[SUP] 1 [/SUP], Ziad Basyouni[SUP] 2 [/SUP], Gideon Meyerowitz Katz[SUP] 2 [/SUP], Vahid Karkvandi[SUP] 2 [/SUP], Leanne Watson[SUP] 2 3 [/SUP], Helen Crowther[SUP] 1 [/SUP], Scott Read[SUP] 1 3 4 [/SUP], Matthew V N O'Sullivan[SUP] 5 6 7 [/SUP], Jasmin Ellis[SUP] 2 [/SUP], Joanne Medlin[SUP] 2 [/SUP], Golo Ahlenstiel[SUP] 1 2 3 4 [/SUP]
Affiliations
Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.
Keywords: COVID‐19; Delta; Omicron BA.2; SARS‐CoV‐2; hospitalisation; monoclonal; sotrovimab.
. 2025 Feb;97(2):e70235.
doi: 10.1002/jmv.70235. Real-World Effectiveness of Sotrovimab in Patients Infected With SARS-CoV-2 Omicron Subvariant BA.2 in Western Sydney, Australia
Eric Kalo[SUP] 1 [/SUP], Ziad Basyouni[SUP] 2 [/SUP], Gideon Meyerowitz Katz[SUP] 2 [/SUP], Vahid Karkvandi[SUP] 2 [/SUP], Leanne Watson[SUP] 2 3 [/SUP], Helen Crowther[SUP] 1 [/SUP], Scott Read[SUP] 1 3 4 [/SUP], Matthew V N O'Sullivan[SUP] 5 6 7 [/SUP], Jasmin Ellis[SUP] 2 [/SUP], Joanne Medlin[SUP] 2 [/SUP], Golo Ahlenstiel[SUP] 1 2 3 4 [/SUP]
Affiliations
- PMID: 39945377
- DOI: 10.1002/jmv.70235
Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA.1 or BA.2, compared to Delta patients (hazard ratio of 0.97 [0.36-2.64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.
Keywords: COVID‐19; Delta; Omicron BA.2; SARS‐CoV‐2; hospitalisation; monoclonal; sotrovimab.